Kees Brinkman

12.1k citations

139 papers · 6.2k · 3 hit papers · h-index 39

Impact in

Virology top 0.2%
- HIV Research and Treatment
Emergency Medicine top 0.05%
- HIV-related health complications and treatments

Papers in

Infectious Diseases 61
- HIV/AIDS drug development and treatment 31
- HIV/AIDS Research and Interventions 27
Virology 26
- HIV Research and Treatment 26

Co-authors: Peter Reiss (29 shared papers)Jan Smeıtınk (2 shared papers)David M. Burger (11 shared papers)Johannes A. Romijn (1 shared paper)Peter P. Koopmans (5 shared papers)Ard van Sighem (8 shared papers)Hadewych J. M. ter Hofstede (3 shared papers)Frank de Wolf (3 shared papers)
Journals: AIDS (26 papers)PLoS ONE (7 papers)Clinical Infectious Diseases (5 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (4 papers)HIV Medicine (3 papers)
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Kees Brinkman

135 papers receiving 6.0k citations

Kees Brinkman's Hit Papers

align trajectories log scale

Future challenges for clinical care of an ageing population infected with HIV: a modelling study 2015 · 637 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 The Lancet Infectious Diseases
1999 The Lancet
1998 AIDS

Peers

Countries citing papers authored by Kees Brinkman

Since Specialization

Citations

This map shows the geographic impact of Kees Brinkman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kees Brinkman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kees Brinkman more than expected).

Fields of papers citing papers by Kees Brinkman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kees Brinkman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kees Brinkman. The network helps show where Kees Brinkman may publish in the future.

Co-authors

The 25 scholars most cited alongside Kees Brinkman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kees Brinkman Line = papers co-authored together Kees Brinkman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 139 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy The Lancet ·Kees Brinkman, Jan Smeıtınk, Johannes A. Romijn, Peter Reiss Hit paper breakdown →	1999	678
2	Adverse effects of reverse transcriptase inhibitors AIDS ·Kees Brinkman, Hadewych J. M. ter Hofstede, David M. Burger, Jan Smeıtınk, Peter P. Koopmans Hit paper breakdown →	1998	673
3	Future challenges for clinical care of an ageing population infected with HIV: a modelling study The Lancet Infectious Diseases ·Mikaëla Smit, Kees Brinkman, Suzanne E. Geerlings, Colette Smit, Kalyani Thyagarajan, Ard van Sighem, Frank de Wolf, Timothy B. Hallett Hit paper breakdown →	2015	637
4	Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals AIDS ·Ard van Sighem, Luuk Gras, Peter Reiss, Kees Brinkman, Frank de Wolf	2010	305
5	Increase in HCV Incidence among Men Who Have Sex with Men in Amsterdam Most Likely Caused by Sexual Transmission The Journal of Infectious Diseases ·Thijs van de Laar, Akke K. van der Bij, Maria Prins, Sylvia M. Bruisten, Kees Brinkman, Thomas A. Ruys, Jan T. M. van der Meer, Henry J.C. de Vries, Jan‐Willem Mulder, Michiel A. van Agtmael, Suzanne Jurriaans, Katja C. Wolthers, Roel A. Coutinho	2007	219
6	Mortality and progression to AIDS after starting highly active antiretroviral therapy AIDS ·Ard I. van Sighem, Mark A. van de Wiel, Azra C. Ghani, Mariëlle Jambroes, Peter Reiss, Inge C. Gyssens, Kees Brinkman, Joep M. A. Lange, Frank de Wolf	2003	143
7	Low Plasma Concentrations of Indinavir are Related to Virological Treatment Failure in HIV-1-Infected Patients on Indinavir-Containing Triple Therapy Antiviral Therapy ·David M. Burger, Richard M. W. Hoetelmans, Patricia W. H. Hugen, Jan W. Mulder, Pieter L. Meenhorst, Peter P. Koopmans, Kees Brinkman, Monique Keuter, W.M.V. Dolmans, Yechiel A. Hekster	1998	140
8	Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Indicator Diseases across Europe Study) PLoS ONE ·Ann Sullivan, Dorthe Raben, Joanne Reekie, Michael Rayment, Amanda Mocroft, Stefan Eßer, Agathe León, Josip Begovać, Kees Brinkman, Robert Zangerle, Anna Grzeszczuk, Anna Vassilenko, Vesna Hadžiosmanović, (unknown), Anders Sönnerborg, Nathan Clumeck, José M. Gatell, Brian Gazzard, Antonella d’Arminio Monforte, Jürgen K. Rockstroh, Jens Lundgren	2013	138
9	Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice AIDS ·Mark de Boer, Guido E.L. van den Berk, Natasja van Holten, Josephine E. Oryszcyn, W. Dorama, Daoud Ait Moha, Kees Brinkman	2016	138
10	Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals AIDS ·David M. Burger, Patricia W. H. Hugen, Peter Reiss, Inge C. Gyssens, M. M. E. Schneider, Frank P. Kroon, Gerrit Schreij, Kees Brinkman, Clemens Richter, Jan M. Prins, Rob E. Aarnoutse, Joep M. A. Lange	2003	121
11	Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM AIDS ·Femke A.E. Lambers, Maria Prins, Xiomara V. Thomas, Richard Molenkamp, David Kwa, Kees Brinkman, Jan T. M. van der Meer, Janke Schinkel	2011	114
12	Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Current Opinion in Infectious Diseases ·Kees Brinkman, Thomas N. Kakuda	2000	107
13	First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir AIDS ·Marit GA van Vonderen, Paul Lips, Michiel A. van Agtmael, Elly A. Hassink, Kees Brinkman, Suzanne E. Geerlings, Jussi Sutinen, Matti Ristola, Sven A. Danner, Peter Reiss	2009	83
14	Anti-DNA antibodies and lupus nephritis: the complexity of crossreactivity Immunology Today ·Kees Brinkman, Rose-Marie Termaat, Jo H. M. Berden, Ruud J.T. Smeenk	1990	78
15	Cross-reactivity of monoclonal anti-DNA antibodies with heparan sulfate is mediated via bound DNA/histone complexes Journal of Autoimmunity ·Rose-Marie Termaat, Kees Brinkman, F. Van Gompel, Lambert P.W.J. van den Heuvel, Jacques H. Veerkamp, Ruud J.T. Smeenk, Jo H. M. Berden	1990	75
16	Factors associated with presenting late or with advanced HIV disease in the Netherlands, 1996–2014: results from a national observational cohort BMJ Open ·Eline Op de Coul, Ard van Sighem, Kees Brinkman, Birgit HB van Benthem, (unknown), Suzanne E. Geerlings, Peter Reiss	2016	72
17	Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA Cohort AIDS ·Jeanne P. Dieleman, Mariëlle Jambroes, Inge C. Gyssens, Miriam Sturkenboom, Bruno H. Stricker, W. Mulder, Frank de Wolf, Gerrit‐Jan Weverling, Joep M. A. Lange, Peter Reiss, Kees Brinkman	2002	66
18	No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial PLoS Medicine ·Marlous L. Grijsen, Radjin Steingrover, Ferdinand W N M Wit, Suzanne Jurriaans, Annelies Verbon, Kees Brinkman, (unknown), Robin Soetekouw, Frank de Wolf, Joep M. A. Lange, Hanneke Schuitemaker, Jan M. Prins, (unknown)	2012	66
19	HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy AIDS ·Radjin Steingrover, Katalyn Pogány, E. Fernández García, Suzanne Jurriaans, Kees Brinkman, Hanneke Schuitemaker, Frank Miedema, Joep MA Lange, Jan M. Prins	2008	65
20	Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases International Journal of STD & AIDS ·Hadewych J. M. ter Hofstede, Siem de Marie, Norbert A. Foudraine, Sven A. Danner, Kees Brinkman	2000	62

About Kees Brinkman

Kees Brinkman is a scholar working on Infectious Diseases, Virology, Epidemiology, Emergency Medicine and Hepatology, having authored 139 papers that have together received 6.2k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (31 papers), HIV/AIDS Research and Interventions (27 papers), HIV Research and Treatment (26 papers), HIV-related health complications and treatments (22 papers), Hepatitis C virus research (15 papers), Monoclonal and Polyclonal Antibodies Research (9 papers), Hepatitis B Virus Studies (8 papers) and Systemic Lupus Erythematosus Research (7 papers). The work is most often cited by research in Virology (1.5k citations), Emergency Medicine (1.9k citations), Infectious Diseases (2.8k citations), Hepatology (530 citations) and Epidemiology (1.1k citations). Kees Brinkman has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Peter Reiss, Jan Smeıtınk, David M. Burger, Johannes A. Romijn, Peter P. Koopmans, Ard van Sighem, Hadewych J. M. ter Hofstede, Frank de Wolf, Suzanne E. Geerlings and Colette Smit. Their work appears in journals such as AIDS, PLoS ONE, Clinical Infectious Diseases, JAIDS Journal of Acquired Immune Deficiency Syndromes and HIV Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Kees Brinkman

Impact in

Papers in i

In The Last Decade

Kees Brinkman

Kees Brinkman's Hit Papers

Peers

Countries citing papers authored by Kees Brinkman

Fields of papers citing papers by Kees Brinkman

All Works

About Kees Brinkman

Explore authors with similar magnitude of impact

Papers in